Navigation Links
Analysis of breast-cancer gene role offers promising target

Researchers at UT Southwestern Medical Center have for the first time described how multiple copies of a gene are responsible for metastases in early-stage breast cancer and poor prognosis for patients.

In a study published in this week's issue of the Proceedings of the National Academy of Sciences, the gene, called uPAR, offers a promising target for therapeutic drugs to stop or slow the progression of the disease and could serve as a screening tool for assessing which types of drugs a patient will respond to.

The gene launches a biochemical process in which a molecule called plasmin perforates the membranes of tissues, causing the membranes to break down and allowing the cancer cells to escape into the bloodstream and to adjacent tissues. The result is metastasizing breast cancer. About 20 percent to 25 percent of breast-cancer patients were shown to have uPAR gene amplification, which means they carry too many copies of the gene.

"The uPAR system probably plays a role in metastases in many of the common solid tumors," said Dr. Jonathan Uhr, professor in the Cancer Immunobiology Center and of microbiology and the study's senior author.

While analyzing slides of individual tumor cells ?either from the primary tumor or circulating tumor cells ?of 72 patients with advanced recurrent breast carcinoma, the UT Southwestern research team discovered how uPAR may work in concert with another known breast cancer gene, HER-2.

The researchers suggest that uPAR may amplify the cancer-causing effects of HER-2.

"This gene, uPAR, is an important oncogene, and that is why we determined whether or not it is amplified," said Dr. Uhr. "Unexpectedly, it is usually amplified in the same tumor cell with HER-2 gene amplification. This has significant implications for treatment with targeting agents. Moreover, we stress the value of individual tumor cell analysis for providing information that cannot be obtained by co nventional pathological examination."

Dr. Debu Tripathy, professor of internal medicine, director of the Komen/UT Southwestern Breast Cancer Research Program and a coauthor of the study, said the biochemical process triggered by uPAR, called the urokinase plasminogen activator system, is one of the breast-cancer prognostic factors that has the greatest level of evidence.

"All the work has been on the protein and enzymatic activity and not amplification of the gene, which is a very reliable and easy-to-use diagnostic test called FISH," said Dr. Tripathy. "The other important finding is that HER-2 and uPAR gene amplification tend to co-exist, and this has implications in new strategies to address HER-2-positive breast cancer with drugs that block both HER-2 and urokinase given together."

The study opens a promising avenue to increase the effectiveness of the drug trastuzumab (Herceptin) by adding a second drug seeking to neutralize the uPAR gene.

"One major avenue of investigation would be to develop an antibody that prevents uPAR from binding to a molecule called uPA that can activate uPAR," Dr. Uhr said.
'"/>

Source:UT Southwestern Medical Center


Related biology news :

1. Ariadne Genomics Announces the Release of PathwayStudio?Central, Client-Server Software for Biological Pathway Analysis
2. Eliminate Data Analysis Bottlenecks in Drug Discovery
3. Analysis Of Human Genome To Predict The Development Of Illnesses
4. Analysis of flower genes reveals the fate of an ancient gene duplication
5. Genomatix Microarray Analysis Pipeline achieves Affymetrix GeneChip compatible?status
6. Analysis of rhesus monkey genome uncovers genetic differences with humans, chimps
7. Research links protein to breast-cancer migration
8. Protein offers way to stop microscopic parasites in their tracks
9. Gene silencing technique offers new strategy for treating, curing disease
10. Mosaic mouse technique offers a powerful new tool to study diseases and genetics
11. Engineered skin offers clues to melanoma development

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/19/2017)... Oregon and PUNE, India , January 19, 2017 ... Research, titled, "Global Biometric Sensor Market, Opportunities and Forecast, 2014 - 2022," ... growing at a CAGR of 9.6% from 2016 to 2022. In 2015, ... owing to high-level security for both public and private sectors. ... ...
(Date:1/19/2017)... 2017 Sensory Inc ., a ... for consumer electronics, and i nnerCore ... cybersecurity solutions, today announced a global partnership that ... worldwide to bolster security of data sensitive mobile ... authentication platforms they offer, innerCore now offers its ...
(Date:1/18/2017)... 18, 2017  In vitro diagnostic (IVD) companies were ... acquisitions (M&A), and Kalorama Information expects that trend to ... been shifting. Generally, uncertainty in reimbursement and healthcare reform ... has changed the acquisitions landscape. Instead of looking to ... buying partners outside of their home country and also ...
Breaking Biology News(10 mins):
(Date:1/18/2017)... 2017 Applied BioMath ( www.appliedbiomath.com ), ... research and development, today announced that Dr. ... of Applied BioMath, will present at the next ... Meeting on Thursday January 19, 2017 at the ... MA.   Dr. Burke,s talk "Quantitative Modeling and Simulation ...
(Date:1/18/2017)... ... January 18, 2017 , ... ... Leven successfully implanted SpineFrontier’s A-CIFT™ Solofuse-P™. The operation took place on Wednesday, January ... NY. The procedure was an anterior cervical discectomy and fusion on a 42 ...
(Date:1/18/2017)... ... January 18, 2017 , ... MYOLYN, which creates medical technology ... a 510(k) to the FDA, requesting clearance of the MyoCycle Home and the ... technology. , The submission marks a major milestone for the technology startup. ...
(Date:1/18/2017)... ... January 18, 2017 , ... BidMed, LLC, announced it will ... genetic testing lab equipment from two different leading institutes. This highly specialized laboratory equipment ... the United States. This 1-day online auction will take place on BidMed’s website ...
Breaking Biology Technology: